Beliefs about medicines' association with endocrine therapy adherence in early breast cancer survivors in Croatia.

IF 2.1 4区医学 Q3 PHARMACOLOGY & PHARMACY

Acta Pharmaceutica Pub Date : 2023-12-26 Print Date: 2023-12-01 DOI:10.2478/acph-2023-0043

Ana Dugonjić Okroša, Tajana Silovski, Natalija Dedić Plavetić, Hrvoje Silovski, Ana Kovačić, Iva Mucalo

{"title":"Beliefs about medicines' association with endocrine therapy adherence in early breast cancer survivors in Croatia.","authors":"Ana Dugonjić Okroša, Tajana Silovski, Natalija Dedić Plavetić, Hrvoje Silovski, Ana Kovačić, Iva Mucalo","doi":"10.2478/acph-2023-0043","DOIUrl":null,"url":null,"abstract":"This observational, cross-sectional study conducted at the University Hospital Centre Zagreb (UHC Zagreb) aimed to explore patients' beliefs about adjuvant endocrine therapy (AET) as well as their association with non-adherence and sociodemographic and clinical factors. Out of 420 early breast cancer (BC) patients included in the study, 79.5 % perceived AET necessary and important for their health, as measured by the Belief About Medicines Questionnaire (BMQ), with the mean necessity score (20.4 ± 3.68) significantly higher than the mean concerns score (13 ± 4.81) (p < 0.001). Based on the Medication Adherence Report Scale (MARS-5), 44.4 % (n = 182) of the participants were non-adherers, out of which 63.2 % (n = 115) were unintentional and 36.8 % (n = 67) intentional non-adherers. Significantly higher concern beliefs were found among patients that were younger (p < 0.001), employed (p < 0.001), intentionally non-adherent to AET (p = 0.006), had a lower body-mass index (p = 0.005) and a higher level of education (p < 0.001), were premenopausal at the time of diagnosis (p < 0.001), taking tamoxifen treatment (p = 0.05) and receiving ovarian suppression (p < 0.001). Younger patients should be recognized as being at risk of non-adherence as they hold greater concern beliefs about medicines.","PeriodicalId":7034,"journal":{"name":"Acta Pharmaceutica","volume":"73 4","pages":"673-689"},"PeriodicalIF":2.1000,"publicationDate":"2023-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Pharmaceutica","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2478/acph-2023-0043","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/12/1 0:00:00","PubModel":"Print","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

This observational, cross-sectional study conducted at the University Hospital Centre Zagreb (UHC Zagreb) aimed to explore patients' beliefs about adjuvant endocrine therapy (AET) as well as their association with non-adherence and sociodemographic and clinical factors. Out of 420 early breast cancer (BC) patients included in the study, 79.5 % perceived AET necessary and important for their health, as measured by the Belief About Medicines Questionnaire (BMQ), with the mean necessity score (20.4 ± 3.68) significantly higher than the mean concerns score (13 ± 4.81) (p < 0.001). Based on the Medication Adherence Report Scale (MARS-5), 44.4 % (n = 182) of the participants were non-adherers, out of which 63.2 % (n = 115) were unintentional and 36.8 % (n = 67) intentional non-adherers. Significantly higher concern beliefs were found among patients that were younger (p < 0.001), employed (p < 0.001), intentionally non-adherent to AET (p = 0.006), had a lower body-mass index (p = 0.005) and a higher level of education (p < 0.001), were premenopausal at the time of diagnosis (p < 0.001), taking tamoxifen treatment (p = 0.05) and receiving ovarian suppression (p < 0.001). Younger patients should be recognized as being at risk of non-adherence as they hold greater concern beliefs about medicines.

查看原文本刊更多论文

克罗地亚早期乳腺癌幸存者对药物的信念与坚持内分泌治疗的关系。

这项观察性横断面研究在萨格勒布大学医院中心（UHC Zagreb）进行，旨在探讨患者对辅助内分泌治疗（AET）的信念及其与不依从性、社会人口学和临床因素的关系。在参与研究的420名早期乳腺癌（BC）患者中，79.5%的患者认为辅助内分泌治疗对其健康是必要且重要的，这是由 "对药物的信念问卷"（BMQ）测量得出的结果，其中必要性的平均得分（20.4 ± 3.68）明显高于关注的平均得分（13 ± 4.81）（P < 0.001）。根据用药依从性报告量表（MARS-5），44.4%（n = 182）的参与者为不依从者，其中 63.2%（n = 115）为无意不依从者，36.8%（n = 67）为有意不依从者。年轻（p < 0.001）、有工作（p < 0.001）、有意不坚持 AET（p = 0.006）、体重指数较低（p = 0.005）、受教育程度较高（p < 0.001）、确诊时绝经前（p < 0.001）、服用他莫昔芬（p = 0.05）和接受卵巢抑制（p < 0.001）的患者的担忧信念明显较高。应认识到年轻患者有可能不坚持用药，因为他们对药物抱有更多的担忧。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Pharmaceutica PHARMACOLOGY & PHARMACY-

CiteScore

5.20

自引率

3.60%

发文量

审稿时长

>12 weeks

期刊介绍： AP is an international, multidisciplinary journal devoted to pharmaceutical and allied sciences and contains articles predominantly on core biomedical and health subjects. The aim of AP is to increase the impact of pharmaceutical research in academia, industry and laboratories. With strong emphasis on quality and originality, AP publishes reports from the discovery of a drug up to clinical practice. Topics covered are: analytics, biochemistry, biopharmaceutics, biotechnology, cell biology, cell cultures, clinical pharmacy, drug design, drug delivery, drug disposition, drug stability, gene technology, medicine (including diagnostics and therapy), medicinal chemistry, metabolism, molecular modeling, pharmacology (clinical and animal), peptide and protein chemistry, pharmacognosy, pharmacoepidemiology, pharmacoeconomics, pharmacodynamics and pharmacokinetics, protein design, radiopharmaceuticals, and toxicology.